---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: C1 esterase inhibitors"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: C1 esterase inhibitors. Topics: International/Canadian guideline: first-line long-term prophylaxis options, Subcutaneous plasma-derived C1 inhibitor: indication and dosing, Intravenous plasma-derived C1 inhibitor: indication and dosing, and Subcutaneous and intravenous routes: guideline comparison. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/c1-esterase-inhibitors"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: C1 esterase inhibitors

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 C1 Esterase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

### International/Canadian guideline: first-line long-term prophylaxis options

> “Berotralstat, donidalorsen, garadacimab, lanadelumab, or pdC1INH could be used as first-line therapy for long-term prophylaxis in patients with HAE due to C1INH deficiency.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.1-2"></a>

### Subcutaneous plasma-derived C1 inhibitor: indication and dosing

> “HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.”
> “Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="topic-2.2.2.1.1-3"></a>

### Intravenous plasma-derived C1 inhibitor: indication and dosing

> “CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).”
> “1,000 IU Intravenous every 3 or 4 days”
> “Doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered based on individual patient response.”

Source: [FDA (2022)](https://www.fda.gov/media/75907/download)

<a id="topic-2.2.2.1.1-4"></a>

### Subcutaneous and intravenous routes: guideline comparison

> “SC administration of pdC1-INH results in more consistent plasma C1-INH concentrations than the IV route and mitigates venous access–related complications, such as thrombosis risk.”
> “When first-line treatments are unavailable, IV pdC1-INH (approved for LTP in some countries) is a second-line option, supported by scientific evidence of its efficacy.”
> “However, it has disadvantages, such as the need for venous access, high cost, and frequent administrations due to its short half-life.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
